BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22561907)

  • 1. External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.
    Zhu Y; Wang JY; Shen YJ; Dai B; Ma CG; Xiao WJ; Lin GW; Yao XD; Zhang SL; Ye DW
    Asian J Androl; 2012 Sep; 14(5):738-44. PubMed ID: 22561907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
    Gomez Gomez E; Salamanca Bustos JJ; Carrasco Valiente J; Fernandez Rueda JL; Blanca A; Valero Rosa J; Bravo Arrebola I; Marquez López J; Jimenez Vacas JM; Luque R; Requena Tapia MJ
    BMJ Open; 2019 Nov; 9(11):e031032. PubMed ID: 31722940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer risk assessment tools in an unscreened population.
    Lundon DJ; Kelly BD; Foley R; Loeb S; Fitzpatrick JM; Watson RW; Rogers E; Durkan GC; Walsh K
    World J Urol; 2015 Jun; 33(6):827-32. PubMed ID: 25091862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.
    Poyet C; Nieboer D; Bhindi B; Kulkarni GS; Wiederkehr C; Wettstein MS; Largo R; Wild P; Sulser T; Hermanns T
    BJU Int; 2016 Mar; 117(3):401-8. PubMed ID: 26332503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
    Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
    World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
    Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
    J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
    Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
    BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
    Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
    BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy.
    Chen R; Xie L; Xue W; Ye Z; Ma L; Gao X; Ren S; Wang F; Zhao L; Xu C; Sun Y;
    Urol Oncol; 2016 Sep; 34(9):416.e1-7. PubMed ID: 27185342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study.
    Wu YS; Zhang N; Liu SH; Xu JF; Tong SJ; Cai YH; Zhang LM; Bai PD; Hu MB; Jiang HW; Na R; Ding Q; Sun YH
    Asian J Androl; 2016; 18(6):925-929. PubMed ID: 27212127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.
    van den Bergh RC; Roobol MJ; Wolters T; van Leeuwen PJ; Schröder FH
    BJU Int; 2008 Nov; 102(9):1068-73. PubMed ID: 18715246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
    Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
    Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population.
    Foley RW; Lundon DJ; Murphy K; Murphy TB; Galvin DJ; Watson RW
    Ir J Med Sci; 2015 Sep; 184(3):701-6. PubMed ID: 25843017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.
    Carbunaru S; Nettey OS; Gogana P; Helenowski IB; Jovanovic B; Ruden M; Hollowell CMP; Sharifi R; Kittles RA; Schaeffer E; Gann P; Murphy AB
    BMC Urol; 2019 Nov; 19(1):121. PubMed ID: 31771578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.
    Jalali A; Foley RW; Maweni RM; Murphy K; Lundon DJ; Lynch T; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Durkan GC; Murphy TB; Watson RW
    BMC Med Inform Decis Mak; 2020 Jul; 20(1):148. PubMed ID: 32620120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
    Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
    Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study.
    De Nunzio C; Lombardo R; Tema G; Alkhatatbeh H; Gandaglia G; Briganti A; Tubaro A
    Urol Oncol; 2018 Aug; 36(8):364.e1-364.e7. PubMed ID: 29880458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.
    Auffenberg GB; Merdan S; Miller DC; Singh K; Stockton BR; Ghani KR; Denton BT
    Urology; 2017 Jun; 104():137-142. PubMed ID: 28237530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population.
    Wu YS; Fu XJ; Na R; Ye DW; Qi J; Lin XL; Liu F; Gong J; Zhang N; Jiang GL; Jiang HW; Ding Q; Xu J; Sun YH
    Asian J Androl; 2019; 21(6):592-597. PubMed ID: 30924451
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.